CTI BioPharma Corp. (CTIC)
Jun 26, 2023 - CTIC was delisted (reason: acquired by Sobi)
9.09
0.00 (0.00%)
Inactive · Last trade price on Jun 23, 2023

CTI BioPharma Statistics

Total Valuation

CTI BioPharma has a market cap or net worth of $1.20 billion. The enterprise value is $1.26 billion.

Market Cap 1.20B
Enterprise Value 1.26B

Important Dates

The last earnings date was Monday, August 7, 2023, after market close.

Earnings Date Aug 7, 2023
Ex-Dividend Date n/a

Share Statistics

CTI BioPharma has 131.88 million shares outstanding. The number of shares has increased by 31.78% in one year.

Current Share Class n/a
Shares Outstanding 131.88M
Shares Change (YoY) +31.78%
Shares Change (QoQ) +2.32%
Owned by Insiders (%) 5.50%
Owned by Institutions (%) 83.29%
Float 99.89M

Valuation Ratios

The trailing PE ratio is -16.23 and the forward PE ratio is -47.81.

PE Ratio -16.23
Forward PE -47.81
PS Ratio 15.82
Forward PS 8.75
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 16.58
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.27

Current Ratio 1.27
Quick Ratio 1.20
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -3.54

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -55.80%
Return on Capital (ROIC) -44.80%
Revenue Per Employee $596,606
Profits Per Employee -$545,189
Employee Count 127
Asset Turnover 0.61
Inventory Turnover 10.15

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +56.19% in the last 52 weeks. The beta is 0.83, so CTI BioPharma's price volatility has been lower than the market average.

Beta (5Y) 0.83
52-Week Price Change +56.19%
50-Day Moving Average 7.53
200-Day Moving Average 5.89
Relative Strength Index (RSI) 83.62
Average Volume (20 Days) 3,272,831

Short Selling Information

The latest short interest is 11.27 million, so 8.55% of the outstanding shares have been sold short.

Short Interest 11.27M
Short Previous Month 8.08M
Short % of Shares Out 8.55%
Short % of Float 11.29%
Short Ratio (days to cover) 1.08

Income Statement

In the last 12 months, CTI BioPharma had revenue of $75.77 million and -$69.24 million in losses. Loss per share was -$0.56.

Revenue 75.77M
Gross Profit 71.31M
Operating Income -53.93M
Pretax Income -69.24M
Net Income -69.24M
EBITDA -51.83M
EBIT -53.98M
Loss Per Share -$0.56
Full Income Statement

Balance Sheet

The company has $59.01 million in cash and $116.46 million in debt, giving a net cash position of -$57.44 million or -$0.44 per share.

Cash & Cash Equivalents 59.01M
Total Debt 116.46M
Net Cash -57.44M
Net Cash Per Share -$0.44
Equity (Book Value) -25.35M
Book Value Per Share -0.19
Working Capital 18.23M
Full Balance Sheet

Cash Flow

Operating Cash Flow -82.32M
Capital Expenditures n/a
Free Cash Flow -82.32M
FCF Per Share -$0.63
Full Cash Flow Statement

Margins

Gross margin is 94.11%, with operating and profit margins of -71.18% and -91.38%.

Gross Margin 94.11%
Operating Margin -71.18%
Pretax Margin -91.38%
Profit Margin -91.38%
EBITDA Margin -68.40%
EBIT Margin -71.24%
FCF Margin -108.64%

Dividends & Yields

CTI BioPharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -31.78%
Shareholder Yield -31.78%
Earnings Yield -5.78%
FCF Yield -6.87%

Analyst Forecast

The average price target for CTI BioPharma is $9.80, which is 7.81% higher than the current price. The consensus rating is "Buy".

Price Target $9.80
Price Target Difference 7.81%
Analyst Consensus Buy
Analyst Count 6
Revenue Growth Forecast (5Y) 59.31%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on January 3, 2017. It was a reverse split with a ratio of 1:10.

Last Split Date Jan 3, 2017
Split Type Reverse
Split Ratio 1:10

Scores

CTI BioPharma has an Altman Z-Score of -27.07 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -27.07
Piotroski F-Score 3